Hint mode is switched on Switch off
For swift navigation between sections

Alaunos Therapeutics

PDF download

Choose all Reset all
Download Cancel
Organization name
Alaunos Therapeutics Inc (formerly ZIOPHARM Oncology, Inc.)
Country name
USA
Country of registration
USA
Industry
Pharmaceutical Preparation and Biotechnology
Public debt
-
Welcome to Cbonds
New to Cbonds? · Take a 90-second tour of the platform.

Discover what you can do with Cbonds

Everything you need for fixed income research and monitoring.

  • 00:23 Coverage
  • 00:40 Bond screener
  • 00:54 Parameters
  • 01:10 Watchlist, Mobile app
  • 01:15 Excel Add-in
Unlock data Watch full tour

Latest data on

Get access to the largest financial database

Try in 7-days Demo access

Free for company representative

  • Evaluate advanced analytical tools
  • Get full online access to the database
  • Try our powerful bond screener
  • Track bond prices from 400+ sources

Get access to the largest financial database

Representative of the company 7 days FREE trial

Professional access to the data

Private investor

Individual access

Quotes

Request sent
Access denied
Send request
Quotes provided by information providers are indicative in nature

Profile

Alaunos is a clinical-stage oncology-focused cell therapy company, focused on developing T-cell receptor (TCR) therapies based on its proprietary, non-viral Sleeping Beauty gene transfer platform and its unique cancer mutation hotspot TCR library, targeting common tumor-related mutations in key oncogenic genes including KRAS, TP53 and EGFR.

Awards

News

09/04/2026 Alaunos Therapeutics: Notice Of Delisting Or Failure To Satisfy A Continued Listing Rule Or Standard; Transfer Of Listing
02/03/2026 Alaunos Therapeutics: Other Events, – Financial Statements And Exhibits
08/01/2026 Alaunos Therapeutics: Termination Of A Material Definitive Agreement, Material Modification To Rights Of Security Holders, Other Events, – Financial Statements And Exhibits
17/12/2025 Alaunos Therapeutics: Entry Into A Material Definitive Agreement, – Financial Statements And Exhibits
19/08/2025 Alaunos Therapeutics: Other Events
All organization news

Documentation

IFRS/US GAAP reports

2026
I q eng
2025
I q eng
II q eng
III q eng
IV q eng
2024
I q eng
II q eng
III q eng
IV q eng
2023
I q eng
II q eng
III q eng
IV q eng
2022
I q eng
II q eng
III q eng
IV q eng
2021
I q eng
II q eng
III q eng
IV q eng
2020
I q eng
II q eng
III q eng
IV q eng
2019
I q eng
II q eng
III q eng
IV q eng
2018
I q eng
II q eng
III q eng
IV q eng
2017
I q eng
II q eng
III q eng
IV q eng
2016
I q eng
II q eng
III q eng
IV q eng
2015
I q eng
II q eng
III q eng
IV q eng
2014
IV q eng
Show all Hide
Authorization required
You need to request access

Stocks

Public debt by currencies

Show more Hide

Codes

  • SIC
    2834 PHARMACEUTICAL PREPARATIONS
  • NACE
    *** ***
  • NAICS
    *** ***
  • CIK
    0001107421
  • EIN
    84-1475642
Registration is required to get access.